REDEFINING THE WAY WE MAKE & TAKE VACCINES.
Millions of people infected.
Billions of people affected.
Trillions of dollars invested.
The world is fighting back.
iosBio is part of that fight.
The OraPro-COVID-19. A coronavirus vaccine that delivers double immunity via a capsule that may be delivered by post that can be swallowed. No needles, no doctors or nurses, no queues for a vaccine, no risk of cross infection.
THERMALLY STABLE, SELF-ADMINISTERED VACCINES IN
CAPSULE FORM ARE THE FUTURE
“The company has taken a harmless virus common in the human body and modified its genetic structure to include two genes that are responsible for the now famous spikes in the coronavirus. It is formulated into a pill that, when digested, would prompt the immune system to produce antibodies to attack the coronavirus spikes. The approach requires small amounts of the drug, meaning it would be easier to manufacture for universal consumption.”
Ralph Vartabedian – The Los Angeles Times
Imagine a world where all vaccines are taken as a capsule – with no needles, no need for cold storage and reduced dependency on healthcare professionals.
OraPro™ is an oral delivery vaccine platform. It effectively delivers non-replicating viral vectors to the gastrointestinal (GI) tract to elicit effective immunity against infectious diseases but not the viral vector itself. iosbio is using OraPro to develop the world’s first oral COVID-19 and Zika vaccines. Research is also underway to develop oral vaccines for several other key diseases, including OraPro-Shingles to provide immunity to the Varicela Zoster Virus, which is affects 1 in 4 adults in their lifetime and was estimated to be worth $2 billion in 2019.
COVID-19 is the perfect example of a novel virus with the ability to rapidly cause a pandemic. In the case of a highly infectious novel virus, the swift development of a vaccine is not enough. An effective vaccine needs to deliver mucosal and systemic immunity combined with how quickly an entire population can be vaccinated.
Using OraPro technology, iosbio OraPro-COVID-19 can be developed within a matter of weeks. The viral vector can be developed within days and a capsule ready for animal testing can be ready within weeks. These stages are now complete, with clinical trials due to begin, pending securing funding. Because OraPro-COVID-19 is delivered in thermally stable capsules, it can be self-administered by patients without the need for needles and healthcare professionals. The delivery mechanism eliminates the risk of potentially infected people queuing for injections, removes the need for cold-chain delivery and enables the world’s most rapid deployment of vaccines.
Burgess Hill, UK, 11 May 2020 STABILITECH BIOPHARMA LTD (“iosBio”), a UK biotechnology company developing next generation vaccines and biopharmaceuticals, announces today that, they have been recognised on a global level by the World Health Organisation (WHO) as a vaccine developer.
iosBio Biopharma strengthens leadership team, as Jeffrey Almond joins the board in the race to develop oral vaccine for COVID-19
PRESS RELEASE iosBio Biopharma strengthens leadership team, as Jeffrey Almond joins the board in the race to develop oral vaccine for COVID-19 Burgess Hill, UK, 07 May 2020 STABILITECH BIOPHARMA LTD (“iosBio”), a UK biotechnology company developing...